Compare KKR & Co Inc (KKR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KKR & Co Inc vs Recursion Pharmaceuticals Inc — how do they compare? KKR & Co Inc trades at $91.07 (market cap $80.39B), while Recursion Pharmaceuticals Inc trades at $4.34 (market cap $2.14B). The key difference: KKR & Co Inc is far larger — about 37.6× Recursion Pharmaceuticals Inc's market cap, and KKR & Co Inc pays a 0.87% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold KKR & Co Inc for 67 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| KKR | RXRX | |
|---|---|---|
Market Cap | $80.39B | $2.14B |
Volume | 6,517,705 | 30,789,535 |
Sector | Financials | Health |
52-Week High | $142.75 | $6.79 |
52-Week Low | $83.88 | $2.84 |
Typical Hold Time | 67 Days | 23 Days |
Enterprise Value | $2.95B | $1.66B |
Dividend Yield | 0.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KKR trades at $90.95, up 1.43% on the day, with strong analyst support showing 24 buy ratings and a $123.30 consensus price target. Recent earnings beat expectations in Q1 and Q2 2026, though Q4 2025 missed. Technical indicators are bearish overall, with RSI levels suggesting potential oversold conditions. The company maintains solid profitability with 14.97% net income margin and continues active portfolio management through recent acquisitions and divestitures.
The investment case for KKR appears favorable given the significant upside to analyst targets and strong institutional support. However, investors face risks from volatile cash flows, high debt levels, and market-sensitive revenue streams. The upcoming Q3 2026 earnings report on November 9 will be crucial for validating current valuation metrics.
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
